{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:57:29Z","timestamp":1776261449523,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-025-04118-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:27:08Z","timestamp":1763987228000},"page":"504-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current status of hematopoietic cell transplantation in patients with peripheral T-cell lymphoma including adult T-cell leukemia\u2013lymphoma"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ohmoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"Suppl 5","key":"4118_CR1","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d'Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108-115.","journal-title":"Ann Oncol"},{"issue":"7","key":"4118_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s11912-023-01400-w","volume":"25","author":"V Milunovi\u0107","year":"2023","unstructured":"Milunovi\u0107 V, Smoljanovi\u0107 IM, Patekar MB, Zatezalo V, Kursar M, Radi\u0107-Kri\u0161to D, et al. First-line therapy for nodal T-cell non-Hodgkin lymphomas: an unmet need in hematology. Curr Oncol Rep. 2023;25(7):813\u201324.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4118_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/hematology.2024000530","volume":"2024","author":"IA Nizamuddin","year":"2024","unstructured":"Nizamuddin IA, Mehta-Shah N. BV and beyond: how to incorporate novel agents into PTCL management. Hematology Am Soc Hematol Educ Program. 2024;2024(1):54\u201361.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"4118_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/hematology.2024000670","volume":"2024","author":"P Dreger","year":"2024","unstructured":"Dreger P, Schmitz N. The role of stem cell transplant (auto and allo) in PTCL and CTCL. Hematology Am Soc Hematol Educ Program. 2024;2024(1):69\u201377.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"4118_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, de Leval L. How i manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851\u201366.","journal-title":"Br J Haematol"},{"issue":"25","key":"4118_CR6","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4118_CR7","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","volume":"107","author":"AM Garc\u00eda-Sancho","year":"2022","unstructured":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, et al. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study. Haematologica. 2022;107(11):2675\u201384.","journal-title":"Haematologica"},{"issue":"19","key":"4118_CR8","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137(19):2646\u201356.","journal-title":"Blood"},{"issue":"32","key":"4118_CR9","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO.24.00554","volume":"42","author":"O Tournilhac","year":"2024","unstructured":"Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, et al. Long-term follow-up of the prospective randomized AATT study (autologous or allogeneic transplantation in patients with peripheral T-cell lymphoma). J Clin Oncol. 2024;42(32):3788\u201394.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4118_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398.","journal-title":"Ann Oncol"},{"issue":"19","key":"4118_CR11","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","volume":"6","author":"KJ Savage","year":"2022","unstructured":"Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022;6(19):5550\u20135.","journal-title":"Blood Adv"},{"issue":"2","key":"4118_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12185-018-2560-x","volume":"109","author":"S Yamasaki","year":"2019","unstructured":"Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, et al. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. Int J Hematol. 2019;109(2):175\u201386.","journal-title":"Int J Hematol"},{"issue":"3","key":"4118_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715\u201323.","journal-title":"Ann Oncol"},{"issue":"2","key":"4118_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41409-018-0223-4","volume":"54","author":"S Fuji","year":"2019","unstructured":"Fuji S, Kurosawa S, Inamoto Y, Murata T, Fuji T, Kim SW, et al. Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma. Bone Marrow Transplant. 2019;54(2):304\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"4118_CR15","doi-asserted-by":"crossref","unstructured":"Iyer SP, Mehta-Shah N, Advani RH, Bartlett NL, Christensen JH, Morschhauser F et al. Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma. Blood Adv 2025.","DOI":"10.1182\/bloodadvances.2024015282"},{"issue":"4","key":"4118_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18(4):652\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"4118_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"DH Yang","year":"2009","unstructured":"Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant. 2009;15(1):118\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"4118_CR18","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4118_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"4118_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6(3):920\u201330.","journal-title":"Blood Adv"},{"issue":"1","key":"4118_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","volume":"13","author":"AC Mamez","year":"2020","unstructured":"Mamez AC, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"4118_CR22","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","volume":"8","author":"M Brink","year":"2024","unstructured":"Brink M, Huisman F, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, et al. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood Adv. 2024;8(14):3619\u201328.","journal-title":"Blood Adv"},{"issue":"5","key":"4118_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","volume":"36","author":"K Kameda","year":"2022","unstructured":"Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022;36(5):1361\u201370.","journal-title":"Leukemia"},{"issue":"2","key":"4118_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.18052","volume":"197","author":"M Savani","year":"2022","unstructured":"Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, et al. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. Br J Haematol. 2022;197(2):212\u201322.","journal-title":"Br J Haematol"},{"issue":"11","key":"4118_CR25","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/s41409-020-0917-2","volume":"55","author":"A Onishi","year":"2020","unstructured":"Onishi A, Inamoto Y, Tajima K, Yamaguchi J, Kawashima I, Kawajiri A, et al. Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant. 2020;55(11):2196\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4118_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1182\/bloodadvances.2024014674","volume":"9","author":"JX Han","year":"2025","unstructured":"Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, et al. Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583\u2013602.","journal-title":"Blood Adv"},{"issue":"6","key":"4118_CR27","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/bjh.20063","volume":"206","author":"MN Sorial","year":"2025","unstructured":"Sorial MN, Han JX, Koh MJ, Boussi L, Li S, Duan R, et al. Forecasting optimal treatments in relapsed\/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study. Br J Haematol. 2025;206(6):1664\u201377.","journal-title":"Br J Haematol"},{"issue":"11","key":"4118_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","volume":"12","author":"A Ohmoto","year":"2019","unstructured":"Ohmoto A, Fuji S. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Rev Hematol. 2019;12(11):975\u201381.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"4118_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101321","volume":"34","author":"M Eapen","year":"2021","unstructured":"Eapen M. Since everyone has a donor, why are some eligible patients still not transplanted? Best Pract Res Clin Haematol. 2021;34(4):101321.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4118_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100990","volume":"62","author":"RJ Jones","year":"2023","unstructured":"Jones RJ, Bacigalupo A. The next horizon now that everyone has a donor: precision allogeneic transplantation. Blood Rev. 2023;62:100990.","journal-title":"Blood Rev"},{"issue":"7","key":"4118_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41409-017-0082-4","volume":"53","author":"S Fuji","year":"2018","unstructured":"Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, et al. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. Bone Marrow Transplant. 2018;53(7):905\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4118_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677\u201387.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4118_CR33","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","volume":"102","author":"S Fuji","year":"2017","unstructured":"Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1258\u201365.","journal-title":"Haematologica"},{"issue":"20","key":"4118_CR34","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","volume":"5","author":"A Ito","year":"2021","unstructured":"Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5(20):4156\u201366.","journal-title":"Blood Adv"},{"key":"4118_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107596","volume":"147","author":"S Fuji","year":"2024","unstructured":"Fuji S. Chemotherapy and allo-HSCT for young patients with aggressive ATL. Leuk Res. 2024;147:107596.","journal-title":"Leuk Res"},{"issue":"1","key":"4118_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.19835","volume":"206","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, et al. Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia\/lymphoma. Br J Haematol. 2025;206(1):235\u201349.","journal-title":"Br J Haematol"},{"issue":"11","key":"4118_CR37","doi-asserted-by":"publisher","first-page":"928.e921","DOI":"10.1016\/j.jtct.2021.07.010","volume":"27","author":"T Tanaka","year":"2021","unstructured":"Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma. Transplant Cell Ther. 2021;27(11):928.e921-928.e927.","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"4118_CR38","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2024014938","volume":"9","author":"T Nagayama","year":"2025","unstructured":"Nagayama T, Fujiwara SI, Nishiwaki S, Wada F, Uchida N, Tanaka M, et al. Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation. Blood Adv. 2025;9(13):3226\u201337.","journal-title":"Blood Adv"},{"issue":"4","key":"4118_CR39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41375-025-02538-1","volume":"39","author":"F Wada","year":"2025","unstructured":"Wada F, Iwasaki M, Hirayama M, Kawamura K, Kaida K, Doki N, et al. Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025;39(4):951\u201361.","journal-title":"Leukemia"},{"issue":"4","key":"4118_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41409-023-01919-3","volume":"58","author":"M Tokunaga","year":"2023","unstructured":"Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, et al. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. Bone Marrow Transplant. 2023;58(4):462\u20134.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4118_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41409-021-01412-9","volume":"57","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, et al. Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone Marrow Transplant. 2022;57(2):323\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"4118_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21037\/sci.2016.09.13","volume":"3","author":"S Fuji","year":"2016","unstructured":"Fuji S, Shindo T. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma. Stem Cell Investig. 2016;3:70.","journal-title":"Stem Cell Investig"},{"issue":"4","key":"4118_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-025-02517-1","volume":"60","author":"S Fuji","year":"2025","unstructured":"Fuji S, Tokunaga M, Kato K, Nakano N, Shindo T, Makiyama J, et al. Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation. Bone Marrow Transplant. 2025;60(4):552\u20134.","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"4118_CR44","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4118_CR45","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/bjh.19231","volume":"204","author":"S Fuji","year":"2024","unstructured":"Fuji S, Yuda S, Tada Y, Kano M, Sanda K, Fujishita K, et al. A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL. Br J Haematol. 2024;204(2):e25\u20137.","journal-title":"Br J Haematol"},{"issue":"8","key":"4118_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17474086.2024.2382300","volume":"17","author":"C Alati","year":"2024","unstructured":"Alati C, Pitea M, Mico MC, Marafioti V, Greve B, Pratico G, et al. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024? Expert Rev Hematol. 2024;17(8):515\u201325.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"4118_CR47","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/14740338.2024.2412236","volume":"23","author":"A Go\u0142os","year":"2024","unstructured":"Go\u0142os A, G\u00f3ra-Tybor J, Robak T. Safety considerations for drugs newly approved for treating acute myeloid leukemia. Expert Opin Drug Saf. 2024;23(11):1393\u2013404.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"4118_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35746","volume":"131","author":"E Gyan","year":"2025","unstructured":"Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, J\u00e4dersten M, et al. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: a phase 2 study. Cancer. 2025;131(4):e35746.","journal-title":"Cancer"},{"issue":"15","key":"4118_CR49","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4118_CR50","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.2024025154","volume":"145","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;145(19):2138\u201348.","journal-title":"Blood"},{"issue":"11","key":"4118_CR51","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1016\/j.clml.2024.07.001","volume":"24","author":"J Yeh","year":"2024","unstructured":"Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, et al. Efficacy and Safety of Gilteritinib versus Sorafenib as post-transplant maintenance in patients with FLT3-ITD acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(11):e819\u201326.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04118-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04118-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04118-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:02:37Z","timestamp":1776258157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04118-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4118"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04118-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}